Open an account

Neutra

NTRR · OTC

$0.0002+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.0002

About NTRR

Neutra Corp. engages in the research and development of modern healthy living solutions. The company is headquartered in Houston, Texas. The company went IPO on 2011-07-12. The firm is engaged in marketing and participating in the nutraceutical space by bringing products derived from all natural and organic origins. The firm plans to research and bring new technology to the Nutraceutical space. The firm is primarily focused on participating in the medical cannabis market, which is a nutraceutical sub-market. The company intends to entrust the manufacturing to a nutraceutical contractor to private label all of its products and to sell them under its brand. The company primarily sells hemp-derived products, including products containing delta-8-THC and other cannabinoids. Its subsidiaries include Diamond Anvil Designs, LLC, Deity Corporation and Vivis Corporation.

Employees
0
Headquarters
Houston, Texas
Listed
Jul 12, 2011
Sector
N/A
Industry
N/A
Website
neutrainc.com

NTRR key statistics

Market cap
583.58K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
8.46M
Volume
101.18M
Open price
$0.0001
High today
$0.0003
Low today
$0.0001
52 Week high
$0.0003
52 Week low
$0.00

Neutra (NTRR) at a glance

As of Oct 28, 2026, Neutra (NTRR) shares are priced at $0.0002, giving the company a market cap of 583.58K and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.0001 and $0.0003. The current price is 100.0% above the day's low and 33.3% below its high.

Volume so far is 101.18M shares, above the average of 8.46M shares a day.

Over the past year Neutra has ranged from $0.00 to $0.0003, and now sits 67% of the way up that range.

NTRR news

  • Press releaseGlobe Newswire

    Neutra Corp's Neutra Life Sciences Expands 2026 Industry Conference Schedule to Deepen Sponsor and CRO Relationships Across Its Site Network

  • Press releaseGlobe Newswire

    Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth

  • Press releaseGlobe Newswire

    Neutra Corp’s Subsidiary Neutra Life Sciences Executes New Women’s Health Joint Venture and Expands Trial Portfolio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.